• Profile
Close

Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid-sparing effect

British Journal of Dermatology Dec 11, 2019

Chen DM, Odueyungbo A, Csinady E, et al. - Through utilizing data gathered in a French investigator-initiated, phase III, open-label, randomized, controlled trial, researchers tested the safety and effectiveness of rituximab and sought approval from health authorities for its use in pemphigus vulgaris (PV). According to disease severity, individuals were randomized to rituximab plus 0.5 or 1.0 mg/kg/day prednisone tapered over 3 or 6 months or 1.0 or 1.5 mg/kg/day prednisone-alone tapered over 12 or 18 months, respectively. The authors discovered that rituximab plus short-term prednisone was more effective than prednisone alone in individuals with moderate to severe PV. Rituximab-treated patients were less exposed to corticosteroids (CS) and less likely to have serious or life-threatening CS-related adverse events. For patients with moderate to severe PV, no new safety issues with rituximab have been reported.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay